Ranbaxy Gets Approval to Set Up Greenfield Manufacturing Facility in Malaysia
Kuala Lumpur, Malaysia; Gurgaon, India, September 13, 2012
Ranbaxy Malaysia Sdn Bhd, a wholly owned subsidiary of Ranbaxy Laboratories Limited today announced that the Government of Malaysia has given approval to the company for setting up a Greenfield manufacturing facility in Malaysia as an EPP (Entry Point Project). The announcement was made by the Prime Minister of Malaysia, The Honourable Dato' Sri Mohd Najib bin Tun Abdul Razak at a ceremony held in Putrajaya, Malaysia today.
Ranbaxy will be investing around RM 125 Million (USD 40 Million) in this project that will provide employment to over 200 people. It will be Ranbaxy's second manufacturing facility in Malaysia.
On the approval of the new manufacturing facility, Arun Sawhney, CEO & Managing Director, Ranbaxy said, "Ranbaxy has been providing high quality, affordable generic pharmaceuticals to the healthcare system of Malaysia for the last 30 years thereby helping the Government to bring down healthcare costs. The setting up of a new manufacturing facility reinforces our commitment to the Malaysian market. In addition to serving the local market the facility will also export products to markets like ASEAN, Middle East, Europe, Sri Lanka, China and other select countries".
The new facility would manufacture dosage forms including tablets and capsules primarily in the Cardiovascular, Anti Diabetic, Anti-infective and Gastrointestinal segments. Ranbaxy's total output in Malaysia will be increased from 1 Billion doses/annum to 3 Billion doses/annum when the new facility is fully operational.
Commenting on the occasion, Jeyabalan Thangarajah, Managing Director, Ranbaxy Malaysia Sdn. Bhd. said, "We are pleased that the Government of Malaysia has approved Ranbaxy's investment in a new manufacturing facility and the project has been accorded Entry Point Project (EPP) status under the Government Economic Transformational Programme (ETP)."
Ranbaxy Malaysia Sdn Bhd recently celebrated 30 years of successful operations in Malaysia. Earlier in the year the company was awarded the 2012 Frost & Sullivan Malaysia Excellence Award for being adjudged the Malaysian Pharmaceutical Company of the Year in the Generics Drug Category.
Ranbaxy Malaysia Sdn Bhd (RMSB) is a joint venture company of Ranbaxy Laboratories Limited, India and Malaysian shareholders. Established in 1982, RMSB is today one of the major generic companies in this market providing medicines in the Cardiovascular, CNS, Anti-infective, Gastroenterology and Anti-viral therapeutic segments. RMSB manufacturing facility in Sungai Petani, Kedah, Malaysia, was commissioned in 1987. RMSB employs over 300 employees in Malaysia.
Ranbaxy Laboratories Limited, India's largest pharmaceutical
company, is an integrated, research based, international
pharmaceutical company producing a wide range of quality,
affordable generic medicines, trusted by healthcare professionals
and patients across geographies. Ranbaxy's continued focus on
R&D has resulted in several approvals, in developed and
emerging markets many of which incorporate proprietary Novel Drug
Delivery Systems (NDDS) and technologies, developed at its own
labs. The company has further strengthened its focus on generics
research and is increasingly working on more complex and specialty
areas. Ranbaxy serves its customers in over 125 countries and has
an expanding international portfolio of affiliates, joint ventures
and alliances, ground operations in 43 countries and manufacturing
operations in 8 countries. Ranbaxy is a member of the Daiichi
Sankyo Group. Through strategic in-licensing opportunities and its
hybrid business model with Daiichi Sankyo, a leading global pharma
innovator headquartered in Tokyo, Japan, Ranbaxy is introducing
many innovator products in markets around the world, where it has a
strong presence. This is in line with the company's commitment to
increase penetration and improve access to medicines, across the
globe. For more information, please visit www.ranbaxy.com.
Posted: September 2012